The Department of Health and Social Care (DHSC) has issued a serious shortage protocol (SSP) for arthritis medicine Salazopyrin 500mg tablets (sulfasalazine), used to reduce joint inflammation, pain and swelling.
The SSP has been issued ‘in response to significant ongoing disruption to the supply of Salazopyrin 500mg tablets,’ the Pharmaceutical Services Negotiating Committee (PSNC) said yesterday (16 March).
The SSPs was introduced yesterday (16 March) and applies to pharmacies in England and Wales.
Under the SSP, pharmacy teams can substitute Salazopyrin 500mg tablets with Sulfasalazine 500mg tablets.
The SSP is set to expire on 25 March but may be ‘amended or revoked at any time’, according to PSNC.
It comes after the SSP for antidepressant fluoxetine 10mg capsules was recently extended again by three months, with the formulation being on the SSP list for three years.
Reimbursement is ‘for the medicine supplied in accordance with the SSP and not the originally prescribed medicine,’ the PSNC said.
This means that under the SSPs, contractors will be reimbursed the drug tariff part VIIIA price for Sulfasalazine 500mg tablets, the negotiator explained.
A full list of SSPs can be found on the NHS Business Services Authority website.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.